Ionis grants Recordati rights to zilganersen for Alexander disease
Summary
Ionis has licensed ex-US rights to zilganersen to Recordati for Alexander disease. Recordati will manage regulatory filings and commercial operations outside the US and support early access initiatives. Ionis will keep US commercialization rights and remain the global lead for development. The deal includes a $30 million upfront payment plus potential milestones and tiered royalties. The drug is already under FDA review, with a PDUFA date set for September 22.
Classifications
industries
No industries detected
applications
No applications detected
AI Classifications
Labels
No AI classifications detected